Pfizer’s COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the product’s first full year on the market, though Pfizer’s revenue forecasts for 2022 came in below analysts’ expectations, sending its shares down by over 5 percent. Called Comirnaty, the company’s two-dose COVID-19 vaccine generated $36.78 billion in revenue for 2021, Pfizer said in its latest quarterly earnings report released Feb. 8 (pdf). Overall, Pfizer’s full-year 2021 revenues came in at $81.3 billion, or 92 percent higher than in 2020. Not counting contributions from Comirnaty and the Pfizer’s COVID-19 antiviral pill Paxlovid, revenues grew by a far more modest 6 percent over the year, to $44.4 billion. “We just concluded a year where we provided tremendous value to society, including to both patients and shareholders,” said Pfizer’s Chief Financial Officer, Frank D’Amelio, in a statement. “In 2021, we exceeded our goal of manufacturing 3 billion …